CJC-1295 (No DAC) + Ipamorelin 5

mg / 5 mg

• PRODUCT DESCRIPTION
• Chemical Information:
• Compound Names:
• CJC-1295 (No DAC) (Mod GRF 1-29)
• Ipamorelin
• Compound Class: Synthetic peptide research compounds
• CJC-1295 (No DAC) Molecular Weight: ~3,357 g/mol
• Ipamorelin Molecular Weight: ~711 g/mol
• Structure:
• CJC-1295 (No DAC): Growth hormone–releasing hormone (GHRH) analog
• Ipamorelin: Growth hormone secretagogue (GHS) peptide
• Form: Lyophilized powder
• Description:
• CJC-1295 (No DAC) + Ipamorelin 5 mg / 5 mg is a research-grade peptide combination
• supplied as a lyophilized powder for controlled laboratory and in-vitro research applications.
• This formulation combines two distinct peptide research compounds commonly studied for
• their complementary roles in endocrine and cellular signaling models.
• CJC-1295 (No DAC), also known as Mod GRF 1-29, is a synthetic analog of growth hormone–
• releasing hormone (GHRH) that is studied for its interaction with GHRH receptors. Ipamorelin
• is a selective growth hormone secretagogue (GHS) commonly utilized in research to evaluate
• ghrelin receptor–mediated signaling pathways.
• When studied together in experimental models, this peptide combination allows researchers
• to investigate coordinated hormonal signaling mechanisms, receptor interactions, and
• downstream cellular processes within controlled laboratory environments.
• Supplied in a stabilized lyophilized powder format, this combination supports precise
• handling and experimental consistency for research professionals.
• Research Applications:
• CJC-1295 (No DAC) + Ipamorelin is actively studied in experimental and laboratory models to
• investigate its potential to:
• Endocrine Signaling Analysis: Examine GHRH and GHS receptor interactions and
• signaling pathways.
• Hormone-Receptor Interaction Studies: Evaluate coordinated receptor binding
• dynamics in controlled research systems.
• Cellular Communication Research: Investigate downstream intracellular signaling
• cascades associated with peptide-mediated pathways.
• Peptide Synergy Models: Support in-vitro studies analyzing combined peptide signaling
• mechanisms.
• Storage and Handling:
• Store lyophilized powder at -20°C.
• After reconstitution, refrigerate at 2–8°C and use promptly.
• Avoid repeated freeze-thaw cycles.
• Handle using aseptic laboratory techniques to maintain sterility and product integrity.
• Product Specifications:
• Potency:
• CJC-1295 (No DAC): 5 mg
• Ipamorelin: 5 mg
• Total Content: 10 mg per vial
• Purity: ≥99% (HPLC verified)
• Appearance: Lyophilized white powder
• Solubility: Soluble in bacteriostatic water or compatible laboratory-grade diluents
• Important Note:
• This product is strictly FOR RESEARCH USE ONLY and is intended exclusively for in-vitro
• research and laboratory experimentation by qualified professionals. It is not a drug, food,
• cosmetic, or dietary supplement and has not been evaluated or approved by the FDA.
• This material is not intended to diagnose, treat, cure, or prevent any disease.
• Introduction into humans or animals is strictly prohibited.
• Any misuse, mislabeling, or misrepresentation may constitute a violation of applicable
• federal, state, or local regulations.
• References:
• Referenced scientific literature includes:
• Thorner, M. O., et al. (1997). Growth Hormone-Releasing Hormone and Analogs.
• Endocrine Reviews.
• Smith, R. G., et al. (1997). Growth Hormone Secretagogues. Endocrine Reviews.